Comparing this vaccine to previous vaccines has a couple of flaws, though. This is the first time we're using mRNA, so it allows for the possibility that it will have effects that other methods haven't. It's also been fast-tracked through the process, in a way that has been consistently identified as "unprecedented". Usually after phase 3 trials you would be able to tick both key boxes: the exceptionally rare effects on particular individuals or groups have been identified through the large sample size, and the long-term effects have been identified through the slow process. The way this process has been managed has introduced new risks. We hope they are almost non-existent but you cannot say that they are, because we haven't done it before. There are some good reasons why it was done that way before.
I believe Rotarix is the last notable vaccine to be created and phase 1 trials started in
2006 (?) and phase 3 trials finished in
2017. Allowing enough time to identify long-term effects is not something they have had to account for before, it just comes naturally. It's not something they've been able to account for this time. Unless you're suggesting there are 0 vaccines that manifested adverse effects that weren't apparent in the first year of trials, then your analogy doesn't work. You're ascribing a risk that is greater than 0 but less than 1, and it's a risk that might well be low, but it's not something you can say with certainty from reading the publications so far.